Asston Pharmaceuticals' board approved raising ₹27.72 crore by issuing 24.10 lakh equity shares at ₹115 each. The move requires shareholder approval at an upcoming EGM, leading to dilution but strengthening the balance sheet.
Asston Pharmaceuticals Board Approves Preferential Allotment to Raise ₹27.72 Crore
24,10,431 equity shares to be issued at ₹115 per share.
Reader Takeaway: Capital infusion boosts balance sheet; shareholder dilution is a concern.
What just happened
Asston Pharmaceuticals Limited's board of directors has approved a plan to raise capital through a preferential allotment of 24,10,431 equity shares. These shares will be issued at a price of ₹115 each (₹10 face value plus ₹105 premium). The total capital to be raised amounts to ₹27.72 crore (₹2,771.99 lakh).
Why this matters
This capital infusion will strengthen Asston Pharmaceuticals' financial position. However, the issuance of new shares will also lead to dilution of the existing shareholders' equity. The company is introducing new non-promoter investors, including Vijay Rathee, who will hold 12.06% post-issue, and Vijaylaxmi Infra Projects Private Limited, holding 7.16% post-issue.
The backstory
Preferential allotments are a common method for companies to raise funds from specific investors without going through a public issue. This often involves strategic investors or entities looking for a significant stake in the company.
What changes now
The company needs to secure shareholder approval for this preferential allotment. An Extraordinary General Meeting (EGM) has been scheduled for July 31, 2026, at 12:30 PM. The meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM) to facilitate participation.
Risks to watch
Existing shareholders may be concerned about the dilution of their stake and the potential impact on future earnings per share. The specific terms of the allotment and the utilization of the funds will be crucial factors.
Peer comparison
Companies in the pharmaceutical sector often resort to capital raising for expansion, research and development, or to manage debt. The pricing of such issuances is typically benchmarked against market prices and intrinsic valuations.
Context metrics (time-bound)
The preferential allotment involves 24,10,431 equity shares at an issue price of ₹115 per share, totaling ₹27.72 crore. The EGM is scheduled for July 31, 2026.
What to track next
Investors should closely monitor the outcome of the EGM on July 31, 2026, and any subsequent announcements regarding the utilization of the ₹27.72 crore raised. Changes in the shareholding pattern post-allotment are also important.